The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2022 | Contemporary approaches to the management of R/R DLBCL
Tycel Phillips, MD, University of Michigan, Ann Arbor, MI, reflects on novel approaches in the management of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), highlighting the approval of axicabtagene ciloleucel (axi-cel), as well as targeted approaches such as polatuzumab vedotin, an antibody-drug conjugate, in combination with bendamustine and rituximab. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
